The Vision of Palobiofarma is to discover the first marketed drug based on a selective adenosine receptor modulator.
Palobiofarma focused internal resources on areas where lies the experience of the management team::
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.
Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona-Iruña, February 27, 2025 – The Navarra biotechnology companies, Palobiofarma and...
Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a...
